Fennec Pharmaceuticals (FENC) Change in Account Payables (2014 - 2025)

Fennec Pharmaceuticals (FENC) has 12 years of Change in Account Payables data on file, last reported at -$1.2 million in Q4 2025.

• Quarterly Change in Account Payables fell 96.65% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (up 359.59% YoY) and the FY2025 annual result came in at $1.4 million, up 359.59% from the prior year.
• Change in Account Payables retreated to -$1.2 million in Q4 2025, from -$75000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.0 million in Q1 2025 to a low of -$1.8 million in Q2 2021.
• A 5-year average of $153150.0 and a median of $252500.0 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2021 — Change in Account Payables jumped 1387.3% — and 2024, when it plunged 1405.17%.
• Tracing FENC's Change in Account Payables over 5 years: stood at -$377000.0 in 2021, then surged by 61.8% to -$144000.0 in 2022, then soared by 681.25% to $837000.0 in 2023, then slumped by 174.79% to -$626000.0 in 2024, then plunged by 96.65% to -$1.2 million in 2025.
• The last three Change in Account Payables figures came in at -$1.2 million (Q4 2025), -$75000.0 (Q3 2025), and $661000.0 (Q2 2025), per Business Quant data.